Renaissance Technologies LLC grew its position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 122.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,651,189 shares of the specialty pharmaceutical company’s stock after buying an additional 5,870,689 shares during the period. Renaissance Technologies LLC owned approximately 3.06% of Valeant Pharmaceuticals Intl worth $221,332,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Sheaff Brock Investment Advisors LLC bought a new stake in Valeant Pharmaceuticals Intl in the 4th quarter valued at $200,000. Cetera Investment Advisers bought a new stake in Valeant Pharmaceuticals Intl during the 4th quarter worth about $208,000. Keybank National Association OH bought a new stake in Valeant Pharmaceuticals Intl during the 4th quarter worth about $208,000. Traynor Capital Management Inc. bought a new stake in shares of Valeant Pharmaceuticals Intl in the 4th quarter valued at about $213,000. Finally, Stephens Inc. AR bought a new stake in shares of Valeant Pharmaceuticals Intl in the 4th quarter valued at about $222,000. 50.12% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on VRX. HC Wainwright upped their target price on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research lowered shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 13th. TD Securities increased their target price on shares of Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Wells Fargo & Co restated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, January 4th. Finally, Goldman Sachs Group initiated coverage on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, January 24th. They set a “sell” rating and a $18.00 price target on the stock. Seven research analysts have rated the stock with a sell rating, ten have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus price target of $18.30.
Valeant Pharmaceuticals Intl Inc (NYSE VRX) traded up $0.87 on Wednesday, hitting $16.95. 18,700,403 shares of the company were exchanged, compared to its average volume of 12,600,000. The company has a debt-to-equity ratio of 4.25, a current ratio of 1.11 and a quick ratio of 0.87. Valeant Pharmaceuticals Intl Inc has a one year low of $8.31 and a one year high of $24.43. The company has a market capitalization of $5,910.00, a price-to-earnings ratio of 4.16, a P/E/G ratio of 0.53 and a beta of -0.28.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a net margin of 27.56% and a return on equity of 42.48%. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.18 billion. During the same quarter in the previous year, the firm posted $1.26 earnings per share. The company’s revenue for the quarter was down 10.0% on a year-over-year basis. analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.12 earnings per share for the current year.
In other news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Thursday, March 8th. The stock was bought at an average price of $15.34 per share, with a total value of $153,400.00. Following the completion of the purchase, the director now owns 106,062 shares in the company, valued at $1,626,991.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Paulson acquired 7,066,629 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Tuesday, March 6th. The shares were purchased at an average cost of $15.40 per share, with a total value of $108,826,086.60. The disclosure for this purchase can be found here. In the last three months, insiders bought 7,121,629 shares of company stock worth $109,702,487. Insiders own 5.87% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/15/valeant-pharmaceuticals-intl-inc-vrx-shares-bought-by-renaissance-technologies-llc.html.
Valeant Pharmaceuticals Intl Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.